Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,726
  • Shares Outstanding, K 55,584
  • Annual Sales, $ 9,190 K
  • Annual Income, $ -101,060 K
  • EBIT $ -78 M
  • EBITDA $ -60 M
  • 60-Month Beta 3.08
  • Price/Sales 5.91
  • Price/Cash Flow N/A
  • Price/Book 0.91

Options Overview Details

View History
  • Implied Volatility 169.35% ( +9.55%)
  • Historical Volatility 118.93%
  • IV Percentile 73%
  • IV Rank 37.25%
  • IV High 446.05% on 12/19/24
  • IV Low 5.12% on 03/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 685
  • Open Int (30-Day) 494

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.06
  • Number of Estimates 1
  • High Estimate 0.06
  • Low Estimate 0.06
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +109.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +36.88%
on 12/27/24
2.23 -13.45%
on 01/06/25
-0.07 (-3.50%)
since 12/06/24
3-Month
1.41 +36.88%
on 12/27/24
2.23 -13.45%
on 01/06/25
-0.03 (-1.53%)
since 10/08/24
52-Week
1.41 +36.88%
on 12/27/24
3.38 -42.90%
on 05/06/24
-1.08 (-35.88%)
since 01/08/24

Most Recent Stories

More News
Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't?

Investors in Cellectis S.A. CLLS need to pay close attention to the stock based on moves in the options market lately. That is because the May 16, 2025 $5 Call had some of the highest implied volatility...

CLLS : 1.93 (-8.10%)
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

ALLO : 2.35 (unch)
NVDA : 140.11 (-0.02%)
IOVA : 7.17 (-3.11%)
AZN : 66.58 (-0.09%)
AMZN : 222.13 (+0.01%)
CLLS : 1.93 (-8.10%)
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

CLLS : 1.93 (-8.10%)
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

CLLS : 1.93 (-8.10%)
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

CLLS : 1.93 (-8.10%)
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

CLLS : 1.93 (-8.10%)
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

CLLS : 1.93 (-8.10%)
There's a Lot of Upside For Emerging Gene-Editing Companies

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

CRBU : 1.7200 (-8.02%)
CLLS : 1.93 (-8.10%)
DTIL : 4.50 (-6.05%)
SGMO : 1.2150 (-11.31%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 610.72 (-1.16%)
AAPL : 242.70 (+0.20%)
SESN : 12.5760 (+7.29%)
HOTH : 1.90 (-16.67%)
CLLS : 1.93 (-8.10%)
ORIC : 8.50 (-7.81%)
PFE : 26.86 (-1.00%)
TGTX : 28.77 (+2.75%)
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using...

CLLS : 1.93 (-8.10%)
HGEN : 0.0002 (-84.62%)
OMGA : 0.7675 (-10.57%)

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 2.16
2nd Resistance Point 2.10
1st Resistance Point 2.01
Last Price 1.93
1st Support Level 1.86
2nd Support Level 1.80
3rd Support Level 1.71

See More

52-Week High 3.38
Fibonacci 61.8% 2.63
Fibonacci 50% 2.40
Fibonacci 38.2% 2.16
Last Price 1.93
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar